Related Experiment Video
Updated: Feb 24, 2026
Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
In vitro targeting of colon cancer cells using spiropyrazoline oxindoles
Rute C Nunes1, Carlos J A Ribeiro1, Ângelo Monteiro1
1Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal.
Abstract:
We report on the synthesis and biological evaluation of a library of twenty-three spiropyrazoline oxindoles. The antiproliferative activity of the chemical library was evaluated in HCT-116 p53(+/+) human colon cancer cell line with eight derivatives displaying good activities (IC50<15 μM). To characterize the molecular mechanisms involved in compound antitumoral activity, two spiropyrazoline oxindoles were selected for further studies. Both compounds were able to induce apoptosis and cell cycle arrest at G0/G1 phase and upregulated p53 steady-state levels, while decreasing its main inhibitor MDM2. Importantly, cytotoxic effects induced by spiropyrazolines oxindoles occurred in cancer cells without eliciting cell death in non-malignant CCD-18Co human colon fibroblasts. Additionally, we demonstrated that the combination of spiropyrazoline oxindole 2e with sub-toxic concentrations of the chemotherapeutic agent 5-fluorouracil (5-FU) exerted a synergistic inhibitory effect on HCT-116 colon cancer cell proliferation. Collectively, our results show the potential of spiropyrazoline oxindoles for development of novel anticancer agents.
Insights
New spiropyrazoline oxindoles show promise as anticancer agents. These compounds effectively inhibit colon cancer cell proliferation by inducing apoptosis and cell cycle arrest, with minimal toxicity to healthy cells.
Area of Science:
- Medicinal Chemistry
- Cancer Biology
- Pharmacology
Background:
- The development of novel anticancer agents is crucial for improving cancer treatment outcomes.
- Spiropyrazoline scaffolds represent a promising class of heterocyclic compounds with diverse biological activities.
- Oxindole derivatives have also demonstrated significant therapeutic potential in various diseases, including cancer.
Purpose of the Study:
- To synthesize and evaluate a library of spiropyrazoline oxindole derivatives for antiproliferative activity against human colon cancer cells.
- To elucidate the molecular mechanisms underlying the antitumoral effects of selected spiropyrazoline oxindoles.
- To assess the potential of combining spiropyrazoline oxindoles with conventional chemotherapy for enhanced efficacy.
Main Methods:
- Synthesis of twenty-three spiropyrazoline oxindole derivatives.
- In vitro antiproliferative assays using HCT-116 p53(+/+) human colon cancer cell line.
- Flow cytometry analysis to determine cell cycle distribution and apoptosis induction.
- Western blot analysis to assess the expression levels of p53 and MDM2.
- Cytotoxicity assays on non-malignant CCD-18Co human colon fibroblasts.
- Combination studies with 5-fluorouracil (5-FU).
Main Results:
- Eight spiropyrazoline oxindole derivatives exhibited significant antiproliferative activity (IC50 < 15 μM) against HCT-116 cells.
- Two selected compounds induced apoptosis and G0/G1 cell cycle arrest in cancer cells.
- Upregulation of p53 and downregulation of its inhibitor MDM2 were observed.
- Compounds demonstrated selective toxicity towards cancer cells, sparing non-malignant fibroblasts.
- Combination of spiropyrazoline oxindole 2e with 5-FU showed synergistic inhibition of colon cancer cell proliferation.
Conclusions:
- Spiropyrazoline oxindoles represent a promising class of compounds with potent and selective anticancer activity.
- These agents exert their effects through mechanisms involving apoptosis induction and cell cycle modulation via the p53 pathway.
- The observed synergy with 5-fluorouracil suggests potential for combination therapy in colon cancer treatment.
- Further investigation into spiropyrazoline oxindoles could lead to the development of novel therapeutic strategies for colon cancer.
